One issued patent and four pending patents protect our technology platform.
The National Cancer Institute continues to fund our underpinning research in cancer cachexia.
Tensive Controls technology platform, protected by a family of patents and pending applications, allows us to modify peptides to perform better as drug candidates, with improved half-life, oral activity, and ability to cross the blood-brain barrier.
Tensive Controls Angiotensin (1-7) analog anti-tumor agent has been licensed and is in pre-clinical development. Our cancer cachexia drug candidate is completing pre-clinical development. Discovery programs are in progress with antimicrobial, anti-biofilm and antiviral peptides.
Tensive Controls' lead drug candidate is a peptide therapeutic for cancer cachexia.
The company was formed in 2009 to understand why melanocortin-based peptide drug candidates exhibit adverse cardiovascular side effects and to synthesize analogs free of such side effects as potential drug therapies.
The company recently closed on a Series A financing.
We established Animal Health Specialties LLC to commercialize our technology platform for applications in veterinary medicine and animal production.